Integra LifeSciences Holdings Corporation (NASDAQ:IART) – Equities research analysts at Northcoast Research boosted their Q3 2018 EPS estimates for Integra LifeSciences Holdings Corporation in a note issued to investors on Monday. Northcoast Research analyst D. Keiser now expects that the life sciences company will post earnings of $0.60 per share for the quarter, up from their prior estimate of $0.58.

Other research analysts have also recently issued research reports about the company. TheStreet cut Integra LifeSciences Holdings Corporation from a “b” rating to a “c+” rating in a research report on Thursday, October 26th. Jefferies Group LLC reissued a “buy” rating and issued a $56.00 price objective on shares of Integra LifeSciences Holdings Corporation in a research report on Sunday. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research report on Thursday, October 26th. J P Morgan Chase & Co cut Integra LifeSciences Holdings Corporation from an “overweight” rating to a “neutral” rating and set a $44.00 price objective on the stock. in a research report on Friday. Finally, Wells Fargo & Company cut Integra LifeSciences Holdings Corporation from an “outperform” rating to a “market perform” rating in a research report on Sunday. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Integra LifeSciences Holdings Corporation has a consensus rating of “Buy” and a consensus price target of $53.91.

ILLEGAL ACTIVITY WARNING: “Northcoast Research Weighs in on Integra LifeSciences Holdings Corporation’s Q3 2018 Earnings (IART)” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/10/31/northcoast-research-weighs-in-on-integra-lifesciences-holdings-corporations-q3-2018-earnings-iart.html.

Integra LifeSciences Holdings Corporation (NASDAQ IART) traded up 1.12% during trading on Tuesday, hitting $46.87. 470,886 shares of the stock were exchanged. Integra LifeSciences Holdings Corporation has a 1-year low of $37.71 and a 1-year high of $56.42. The stock has a market cap of $3.66 billion, a price-to-earnings ratio of 57.16 and a beta of 0.72. The firm’s 50 day moving average price is $50.22 and its 200-day moving average price is $50.15.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last released its quarterly earnings results on Thursday, October 26th. The life sciences company reported $0.45 EPS for the quarter, missing the Zacks’ consensus estimate of $0.47 by ($0.02). Integra LifeSciences Holdings Corporation had a net margin of 4.52% and a return on equity of 16.35%. The firm had revenue of $278.83 million during the quarter, compared to the consensus estimate of $286.00 million. During the same period in the prior year, the business earned $0.93 EPS. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year.

Large investors have recently added to or reduced their stakes in the stock. Acrospire Investment Management LLC raised its stake in shares of Integra LifeSciences Holdings Corporation by 280.0% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after purchasing an additional 1,400 shares during the period. Riverhead Capital Management LLC raised its stake in shares of Integra LifeSciences Holdings Corporation by 49.9% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock valued at $131,000 after purchasing an additional 799 shares during the period. LS Investment Advisors LLC raised its stake in shares of Integra LifeSciences Holdings Corporation by 4.6% during the 2nd quarter. LS Investment Advisors LLC now owns 2,523 shares of the life sciences company’s stock valued at $138,000 after purchasing an additional 111 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Integra LifeSciences Holdings Corporation by 8.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock valued at $150,000 after purchasing an additional 218 shares during the period. Finally, Whittier Trust Co. bought a new stake in shares of Integra LifeSciences Holdings Corporation during the 3rd quarter valued at $169,000. Institutional investors own 84.88% of the company’s stock.

In related news, Director Donald E. Morel, Jr. acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 4th. The shares were bought at an average cost of $49.25 per share, for a total transaction of $492,500.00. Following the purchase, the director now owns 29,612 shares in the company, valued at approximately $1,458,391. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Donald E. Morel, Jr. acquired 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The shares were bought at an average price of $49.29 per share, for a total transaction of $123,225.00. Following the completion of the purchase, the director now owns 29,612 shares in the company, valued at approximately $1,459,575.48. The disclosure for this purchase can be found here. Insiders own 21.50% of the company’s stock.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Earnings History and Estimates for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.